Incidence of Thrombocytopenia After Exposure to Abciximab and Impact of Different Treatment Modalities on Platelet Recovery - A Retrospective Study
Journal of Clinical and Basic Cardiology 2002; 5 (3): 257
PDF Summary
Keywords: Abciximab, Glykoprotein-IIb-IIIa-Rezeptorblocker, Kardiologie, Thrombozytopenie, Abciximab, Glykoprotein-IIb-IIIa, IVIG, platelet recovery, thrombocytopenia, treatment
Platelets play an important role in acute coronary syndromes. Platelet glycoprotein IIb/IIIa receptor inhibitors have been used to block the final common pathway of platelet aggregation. The biochemical and pharmacological properties of these agents have been extensively studied. However, the impact of different treatment modalities on platelet recovery has not been compared.
Journal of Clinical and Basic Cardiology 2002; 5 (3): 257
PDF Summary
Keywords: Abciximab, Glykoprotein-IIb-IIIa-Rezeptorblocker, Kardiologie, Thrombozytopenie, Abciximab, Glykoprotein-IIb-IIIa, IVIG, platelet recovery, thrombocytopenia, treatment
Platelets play an important role in acute coronary syndromes. Platelet glycoprotein IIb/IIIa receptor inhibitors have been used to block the final common pathway of platelet aggregation. The biochemical and pharmacological properties of these agents have been extensively studied. However, the impact of different treatment modalities on platelet recovery has not been compared.